Non Applicability of Filing Statement of Deviation/Variation in Utilization of Funds for Quarter and Year Ended 31st March, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Welcure Drugs & Pharmaceuticals has informed BSE that Regulation 32 of SEBI's Listing Obligations and Disclosure Requirements (LODR) does not apply to the company for the fourth quarter and full financial year ended 31st March 2025. The company has confirmed that it did not raise any funds during this period, meaning there is no requirement to file a statement showing any deviation or variation in how those proceeds were used. This is a routine, mandatory disclosure that companies must make every quarter under SEBI rules. The filing was signed by Chintan Didawala Ganpat, Managing Director and CFO of the company.
This is a routine regulatory compliance filing with no material impact on shareholders or the stock price. It simply confirms that no fresh capital was raised during the quarter or the full year, so there is nothing to report regarding fund utilization.